Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERO Trial: Romidepsin and Durvalumab in Localized Bladder Cancer
NCT06963346Phase 1Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Jun 2025
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of romidepsin in bladder cancer (3 arms), sponsored by Moffitt Cancer Center. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Jun 2025; status: recruiting.
02
Drugs
romidepsin
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT06963346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06963346.